Health Care & Life Sciences » Pharmaceuticals | Il Dong Holdings Co. Ltd.

Il Dong Holdings Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
395,231
417,517
38,301
40,771
41,071
47,050
Cost of Goods Sold (COGS) incl. D&A
197,424
217,078
25,876
24,028
24,196
28,511
Gross Income
197,807
200,439
12,424
16,743
16,875
18,539
SG&A Expense
177,739
185,977
17,360
20,499
18,702
18,806
EBIT
20,068
14,462
-
3,756
1,827
267
Unusual Expense
2,706
410
-
121
-
-
Non Operating Income/Expense
3,588
745
189
73
85
13
Interest Expense
5,998
6,952
883
1,509
2,119
2,287
Pretax Income
16,017
9,805
4,869
4,777
175
2,944
Income Tax
7,917
2,443
645
211
198
888
Equity in Affiliates
1,360
312
369
225
-
-
Consolidated Net Income
6,740
11,935
5,144
4,340
23
3,832
Net Income
6,485
11,856
5,496
4,543
652
3,719
Net Income After Extraordinaries
6,485
11,856
31,971
275,074
652
3,719
Net Income Available to Common
6,485
11,856
20,979
13,555
652
3,719
EPS (Basic)
930.14
1,697.16
3,005.61
15,624.00
69.00
363
Basic Shares Outstanding
7
7
7
17
9
10
EPS (Diluted)
929.67
1,697.73
3,004.26
15,624.25
68.90
363.01
Diluted Shares Outstanding
7
7
7
17
9
10
EBITDA
34,296
30,819
3,760
2,347
675
2,664
Non-Operating Interest Income
1,066
1,139
760
682
568
317
Minority Interest Expense
256
79
351
203
628
113
Equity in Affiliates (Pretax)
-
-
-
-
3,118
693

About Il Dong Holdings Co.

View Profile
Address
2 Baumoe-ro 27-gil
Seoul SL 06752
Korea, Republic Of
Employees -
Website http://www.ildong.com
Updated 07/08/2019
Ildong Holdings Co., Ltd. is a business development and investment company, which focuses on pharmaceutical operations. Through its subsidiaries, it also operates in the following industries: Advertisement, Medical Device, Software Development, Plastic Surgery Equipment, Health Food, Hyaluronic Acid and Filler. The company was founded on March 14, 1941 and is headquartered in Seoul, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.